Kona Community Hospital Pharmacy prepared sterile drugs in insanitary conditions with microbial contamination and facility flaws.
What happened
FDA inspected the pharmacy from December 2 to December 13, 2019, and issued a Form FDA 483 (inspection observations form) on December 13, 2019. FDA found sterile drug products were prepared under insanitary conditions, including repeated microbial contamination in cleanrooms and sterile work hoods/cabinets, deficient facility design, inadequate smoke studies, and use of a non-sterile disinfectant in the sterile processing area. FDA said the pharmacy’s January 3, 2020 response did not include enough information or documentation to fully evaluate some corrective actions.
What FDA found
Sterile drug products were prepared under insanitary conditions that could contaminate them, making them adulterated under the law.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The pharmacy did not fix repeated microbial contamination found in cleanrooms and sterile work hoods/cabinets and did not evaluate its impact on drugs.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The cleanroom design was deficient, including an unclamped HEPA filter that had failed leak testing and was not leak-tested in 2019, air returns near supply vents, and doors that could be open at the same time.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The pharmacy could not maintain a differential pressure cascade between rooms of higher and lower air quality when cleanroom doors were closed, and air supply vents had apparent dust.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The pharmacy did not perform adequate smoke studies under dynamic conditions to show unidirectional airflow in the ISO 5 biological safety cabinet.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The pharmacy used a non-sterile disinfectant in the ISO 5 aseptic processing area.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
What FDA wants
Within 15 working days, notify FDA in writing of specific corrective steps, prevention steps, and documentation; if corrections cannot be completed, state why and give a completion date. FDA also strongly recommends a comprehensive assessment of operations, including aseptic processing, with a third-party consultant who has sterile drug manufacturing expertise.
Who should pay attention
- patients receiving compounded sterile drugs from hospital pharmacies
- hospitals and health systems that use compounded sterile products
- compounding pharmacies with sterile cleanrooms
This is a summary. Read the original letter on fda.gov.